Physicians' Academy for Cardiovascular Education

CVRM

Recently added learning

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

The mechanism of action of bempedoic acid

Feb. 2, 2020

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm

Large community-based studies stress the impact of preventive measures

3' education - Sep. 9, 2019 - Paris, France - Prof. Salim Yusuf

Assessing individual CV risk and treatment effect with U-Prevent

10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD

More intelligent intervention through more strategic use of CV biomarkers

3' education - May 28, 2019 - Maastricht, The Netherlands

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Challenges and models in CV risk management: Start early, Invest in your arteries

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA

Possible approaches in precision medicine for secundary CV prevention

10' education - Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Targeting residual inflammatory risk as a strategy to lower CV risk

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
##FULL_TITLE##

CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)

Surviving elevated Lp(a): a patient story from diagnosis to treatment

10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

How to treat residual inflammatory risk?

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Elucidating the role of gut microbes in CVD may provide future therapeutic strategies

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USA
##FULL_TITLE##

HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations

3' education - May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
##FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

3' education - May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

10' education - Sep. 27, 2015
##FULL_TITLE##

Statins are enough for the prevention of CVD

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##FULL_TITLE##

Lipid Management: diagnostics and guidelines

3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##FULL_TITLE##

How to manage statin-intolerant patients?

3' education - June 11, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Erik Stroes
##FULL_TITLE##

Lipids: Who is at real high risk?

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##FULL_TITLE##

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov

CVRM Dubai

10' education - Sep. 15, 2014
##FULL_TITLE##

New British guidelines and risk calculator on CV Risk (JBS3)

3' education - Apr. 7, 2014 - ACC 2014 - Prof John E Deanfield

CV Risk Master Class Latin American chapter

10' education - Nov. 25, 2013

CV Risk Master Class

10' education - Oct. 14, 2013

Online CV Risk Master Class

10' education - Oct. 21, 2013

Online CV Risk Master Class - Español

10' education - Oct. 31, 2013

CardioVascular Risk Master Class

10' education - May 17, 2013

CardioVascular Risk Master Class

10' education - May 17, 2013

CV Risk Master Class - Asian chapter

10' education - May 29, 2013

On demand 10" video

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

Assessing individual CV risk and treatment effect with U-Prevent

10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Challenges and models in CV risk management: Start early, Invest in your arteries

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Possible approaches in precision medicine for secundary CV prevention

10' education - Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Targeting residual inflammatory risk as a strategy to lower CV risk

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Surviving elevated Lp(a): a patient story from diagnosis to treatment

10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
##FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

10' education - Sep. 27, 2015

CVRM Dubai

10' education - Sep. 15, 2014

CV Risk Master Class Latin American chapter

10' education - Nov. 25, 2013

CV Risk Master Class

10' education - Oct. 14, 2013

Online CV Risk Master Class

10' education - Oct. 21, 2013

Online CV Risk Master Class - Español

10' education - Oct. 31, 2013

CardioVascular Risk Master Class

10' education - May 17, 2013

CardioVascular Risk Master Class

10' education - May 17, 2013

CV Risk Master Class - Asian chapter

10' education - May 29, 2013

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. Prof. Hobbs discusses the classic CV risk factors one by one.

Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.

The mechanism of action of bempedoic acid

Feb. 2, 2020

Learn how bempedoic acid an ACL inhibtor works in reducing LDL-c

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD
Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.

Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm
In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

Large community-based studies stress the impact of preventive measures

3' education - Sep. 9, 2019 - Paris, France - Prof. Salim Yusuf
Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

Assessing individual CV risk and treatment effect with U-Prevent

10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD
The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?

The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?

More intelligent intervention through more strategic use of CV biomarkers

3' education - May 28, 2019 - Maastricht, The Netherlands
Prof. Chris Packard distinguishes various types of biomarkers. Thinking about them in this way can provide a framework for more intelligent use of biomarkers.

EAS 2019 Prof. Chris Packard distinguishes various types of biomarkers. Thinking about them in this way can provide a framework for more intelligent use of biomarkers.

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME
Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.

Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.

Cholesterol guidelines in need of major changes?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME
PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands
Current CV risk scores overestimate risk in elderly and underestimate risk in young subjects. Prof. Frank Visseren emphasizes the need of CV lifetime risk prediction and presents the U-prevent calculator that estimates gain in CVD-free life based on lifetime CV risk and treatment effects in individuals.

Current CV risk scores overestimate risk in elderly and underestimate risk in young subjects. Prof. Frank Visseren emphasizes the need of CV lifetime risk prediction and presents the U-prevent calculator that estimates gain in CVD-free life based on lifetime CV risk and treatment effects in individuals.

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Challenges and models in CV risk management: Start early, Invest in your arteries

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom
Prof. John Deanfield introduces a new way of thinking about CV risk management in patients and population, to reduce the burden of CVD in society.

Prof. John Deanfield introduces a new way of thinking about CV risk management in patients and population, to reduce the burden of CVD in society.

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS
Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.

ESC 2018 Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.

Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France
Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

Estimating CV risk and treatment benefit

Clinical updates in management of cardiovascular risk (4/4)

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands - Online CME
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.

Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

The role of lipids in CVD prevention: Lessons learned about statins

Clinical updates in management of cardiovascular risk (2/4)

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME
For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Clinical updates in management of cardiovascular risk For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Early intervention for lifetime CV risk reduction

Clinical updates in management of cardiovascular risk (1/4)

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME
CV risk factors that drive arterial disease in early life have a major impact on future CV risk. Communication about early lifestyle intervention to the public should be a major focus to reduce CV risk in later years.

Clinical updates in management of cardiovascular risk CV risk factors that drive arterial disease in early life have a major impact on future CV risk. Communication about early lifestyle intervention to the public should be a major focus to reduce CV risk in later years.

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA
Laura Stevens presented her poster on using artificial intelligence to identify risk factors for CVD and stroke. The found association with coffee was validated with traditional analyses.

AHA 2017 Laura Stevens presented her poster on using artificial intelligence to identify risk factors for CVD and stroke. The found association with coffee was validated with traditional analyses.

Possible approaches in precision medicine for secundary CV prevention

10' education - Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)
Possible approaches in precision medicine for secundary CV prevention

CSI Rome Nicole Jaspers en Gijs Berkelmans discuss the role of precision medicine in secondary prevention with Dr. Noel Bairey Merz, as well as which approaches and types of data can be considered to assess risk.

Targeting residual inflammatory risk as a strategy to lower CV risk

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
Residual CV risk consists of cholesterol and inflammatory residual risk. How can these aspects be addressed to lower CV risk?

CSI ROME Nicole Jaspers and Manon Slob interview Prof. Paul Ridker about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.

CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)
##KEY_PHRASE##

The SAVE trial evaluated treatment of obstructive sleep apnea with continuous positive airway pressure in patients with CVD. McEvoy concludes there was no benefit for the composite CV endpoint, but a trend for stroke prevention in compliant patients, and QoL measures were improved.

Surviving elevated Lp(a): a patient story from diagnosis to treatment

10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
A patient's perspective of someone with elevated Lp(a), and consequently a high CV risk, despite a healthy lifestyle

Sandra Revill Tremulis, founder of the Lipoprotein(a) Foundation, shares her experiences as a patient with elevated Lp(a), and consequently a high CV risk, despite a healthy lifestyle.

How to treat residual inflammatory risk?

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

In patients with elevated LDL-c and CRP, adding another lipid-lowering therapy may not adequately lower CV risk. Targeting residual inflammatory risk may be an effective strategy for secondary prevention.

Elucidating the role of gut microbes in CVD may provide future therapeutic strategies

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USA
Gut microbes can play a role in physiological processes leading to cardiovascular disease. Specifically targeting microbes that increase levels of the metabolite TMAO, may prove to be a future therapeutic strategy.

Stanley Hazen discusses the connection between our gut microbiome and physiologic processes relevant to heart disease, via a pathway involving the metabolite TMAO.

HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations

3' education - May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
##KEY_PHRASE##

Professor Ray discusses the HOPE-3 trial, in which CV risk was assessed without use of a comprehensive risk calculator. Statin therapy yielded a clear CV event reduction, while BP-lowering therapy did not. Combination therapy was only beneficial when baseline BP was >140 mmHg.

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##KEY_PHRASE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##KEY_PHRASE##

Dr Fitchett provides his perspective on the potential impact of the EMPA REG outcomes trial on the management of T2DM by cardiologists.

Stroke reduction with PPAR-Y antagonist pioglitazone

3' education - May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##KEY_PHRASE##

Dr. Robert Chilton, (Texas) discusses the results of the IRIS trial where treatment with PPAR-γ agonist pioglitazone

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##KEY_PHRASE##

ACC 2016 Prof. Salim Yusuf discusses the results of the HOPE-3 study, which indicates that statins are effective in all patients with intermediate CVD risk, whereas blood pressure lowering is only effective in hypertensive patients.

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##KEY_PHRASE##

The REACH registry demonstrated that CV risk factors are not adequately controlled worldwide. Prof. Deepak Bhatt (Boston, MA, USA) shares the evidence for preventive strategies and considers how the new PCSK9 inhibitors fit into CV risk management.

Diabetes & Cardiovascular Disease:The risk factor to be challenged

Prof John E Deanfield, London, UK

10' education - Sep. 27, 2015
##KEY_PHRASE##

Prof Deanfield discusses the rationale for glucose control and CV risk reduction

Statins are enough for the prevention of CVD

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##KEY_PHRASE##

Prof. Ray defends the proposition 'Statins are enough for the prevention of CVD' and considers the opposing standpoint in the plenary 'Controversy session' entitled 'Statin therapy vs. novel interventions'. Ray thinks more CVD could be prevented if more people globally would have access to statins. Is it time to add statins to drinking water, then?

Lipid Management: diagnostics and guidelines

3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##KEY_PHRASE##

Lipid MC 2015 Prof. Kausik Ray highlights differences in recommendations between international lipid guidelines, which originate in differences between the scopes of the documents. These differences have consequences for the recommended approach to reduce CV risk in patients.

How to manage statin-intolerant patients?

3' education - June 11, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Erik Stroes
##KEY_PHRASE##

Lipid MC 2015 Prof. Erik Stroes emphasises the care and attention needed when managing patients with statin-attributed muscle symptoms. Patients should be counselled on the benefit of statins to reduce CV risk and statin rechallenges may be effective.

Lipids: Who is at real high risk?

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##KEY_PHRASE##

Lipid MC 2015 Prof. Kausik Ray provides several reasons why non-HDL-c may be a better lipid parameter than LDL-c to assess risk, to identify high-risk patients and guide treatment.

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##KEY_PHRASE##

Prof. Susekov, Moscow, with a brief update on current challenges to manage CVD in Russia, including some take home messages for Russian physicians

CVRM Dubai

10' education - Sep. 15, 2014

New British guidelines and risk calculator on CV Risk (JBS3)

3' education - Apr. 7, 2014 - ACC 2014 - Prof John E Deanfield
##KEY_PHRASE##

Prof. John E Deanfield highlights the key messages of JBS3: a new approach to CVD prevention, considering 'lifetime CV risk' and 'heart age'.

CV Risk Master Class Latin American chapter

Applying new insights to clinical practice

10' education - Nov. 25, 2013

CV Risk Master Class

Bogota, Colombia, November 1-2, 2013

10' education - Oct. 14, 2013

Online CV Risk Master Class

Bogota, Colombia, November 1-2, 2013

10' education - Oct. 21, 2013

Online CV Risk Master Class - Español

November 1- 2, 2013, Bogota, Colombia

10' education - Oct. 31, 2013

CardioVascular Risk Master Class

Dubai, Friday May 24, 2013

10' education - May 17, 2013

CardioVascular Risk Master Class

Dubai, Saturday May 25, 2013

10' education - May 17, 2013

CV Risk Master Class - Asian chapter

May 10 -11, 2013, Kuala Lumpur

10' education - May 29, 2013